Fibrocell Science, Inc. announced unaudited consolidated earnings results for the six months ended June 30, 2018. For the six months, the company reported operating loss was $6,058,000 against $9,481,000 a year ago. Loss before income taxes was $5,795,000 against $19,025,000 a year ago. Net loss was $5,795,000 against $19,025,000 a year ago. Net loss attributable to common stockholders was $6,207,000 against $22,995,000 a year ago. Basic and diluted per share was $1.03 against $7.82 a year ago. The company used approximately $7.5 million in cash for operations during the six months ended June 30, 2018, and used approximately $9.0 million in cash for operations during the six months ended June 30, 2017.

Fibrocell expects to enroll a total of six patients ages seven and older by the end of the third quarter of 2018. Fibrocell expects to provide another interim data report and trial update in the first quarter of 2019.